Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating […]
HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating […]
